Please assess the completion status of the following clinical trial:

Trial Title: Exploratory Study of Norepinephrine to Prevent Radiodermatitis in Breast Cancer Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Eligibility Criteria~Subjects must:~* be ≥ age 18 years of age with a documented pathological diagnosis of Stage Ia (T1, N0, M0), Stage Ib (T0 or 1, N1mic, M0) or Stage IIa (T\<3cm, N0, M0) infiltrating ductal or lobular carcinoma of the breast or ductal carcinoma in situ (DCIS).~* be post-surgical patients scheduled to be treated with at least 40 to 50.4 Gy to the whole breast and axilla using either standard or hypofractionated radiation techniques . An additional 10-16 Gy boost to the lumpectomy region may also be delivered. All radiation treatment is to be delivered based on standard CT planning.~* have the ability to understand the informed consent document.~* be able to comply with protocol schedule.~* have a negative serum pregnancy test (within 7 days prior to starting radiation therapy), if a female of child bearing potential.~* consent to utilize medically acceptable methods of contraception throughout the study period if of child-bearing potential.~Exclusion Criteria~Subjects:~* with unhealed surgical wounds or scars in the study treatment area (axilla).~* with underlying active untreated cardiac disease (e.g. arrhythmia).~* with generalized skin disorders that have required treatment within the past 6 months.~* with connective tissue disorders.~* with rashes, ulcerations, or poorly healed scars in the study drug application area (axilla).~* with a known allergy to norepinephrine.~* with known uncontrolled hypertension (repeatedly elevated BP; systolic BP \>139 or diastolic BP \>89).~* with a known clinically significant abnormal ECG within the past 6 months.~* receiving MAO inhibitors or antidepressants (triptyline or imipramine types).~* who are pregnant or breastfeeding.~* with lymphovascular space invasion on pathology.~* with dermal lymphatic invasion on pathology.~* with proximity of the tumor to the overlying skin as evidenced by a distance of less than 5 mm on US or MRI (if performed) and within 2 cm of the anticipated application field~* diagnosis of inflammatory breast cancer.~* receiving chemotherapy other than Herceptin concurrent with the radiation.~* with previous radiation to the breast to be treated.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Norepinephrine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).